RC28-E同时抑制成纤维细胞生长因子-2与血管内皮生长因子-A治疗糖尿病黄斑水肿:一项2期随机试验
这项前瞻性、随机、活性对照、开放标签、多中心2期试验纳入156例中心受累型糖尿病黄斑水肿患者,比较不同剂量和给药方案的RC28-E与康柏西普。24周和52周时各RC28-E组最佳矫正视力(BCVA)和中心亚域厚度(CST)改善与康柏西普组无显著差异;但Per Protocol Set分析显示24周时2.0mgPRN组BCVA改善显著优于康柏西普组(14.0 vs 9.8,p=0.019),且基线血糖控制不佳(HbA1c≥7.5%)患者52周时2.0mgPRN组BCVA改善更优(14.4 vs 4.2,p=0.039),维持期注射次数更少。作者推荐2.0mgPRN方案。
要点
- 2.0mgPRN方案在Per Protocol Set分析中24周BCVA改善显著优于康柏西普(14.0 vs 9.8,p=0.019)。
- 基线HbA1c≥7.5%患者中,2.0mgPRN组52周BCVA改善优于康柏西普组(14.4 vs 4.2,p=0.039)。
- 维持期2.0mgPRN组注射次数少于康柏西普组(2.8次,95%CI 1.8-3.7 vs 4.4次,95%CI 3.5-5.2)。
核心结论
- 玻璃体腔注射RC28-E可改善中心受累型糖尿病黄斑水肿眼的BCVA和CST。
- 与康柏西普相比,作者推荐2.0mgPRN方案,因其在改善视力方面疗效更优,尤其对血糖控制不佳患者,维持期注射次数更少,安全性相当。
研究设计与样本
- 前瞻性、随机、活性对照、开放标签、多中心2期临床试验,纳入156例18岁及以上中心受累型糖尿病黄斑水肿患者,BCVA为73至24个ETDRS字母,CST≥300 µm。
- 患者随机分配至五种方案之一:1.0mgQ8、1.0mgPRN、2.0mgQ8、2.0mgPRN或康柏西普0.5mg(初始3次每月给药后PRN)。
- 主要终点为24周和52周BCVA较基线变化。
主要发现
- 24周BCVA平均改善:1.0mgQ8组7.1字母,1.0mgPRN组11.0字母,2.0mgQ8组7.4字母,2.0mgPRN组10.5字母,康柏西普组9.7字母(p=0.146)。
- 52周BCVA平均改善:1.0mgQ8组5.5字母,1.0mgPRN组9.5字母,2.0mgQ8组9.2字母,2.0mgPRN组9.7字母,康柏西普组8.4字母(p=0.469)。
- 52周CST平均降低:1.0mgQ8组-163.2 µm,1.0mgPRN组-136.9 µm,2.0mgQ8组-142.5 µm,2.0mgPRN组-153.6 µm,康柏西普组-160.7 µm(p=0.948)。
- Per Protocol Set分析显示24周2.0mgPRN组BCVA改善显著优于康柏西普组(14.0 vs 9.8,p=0.019)。
- 基线HbA1c≥7.5%患者中,52周2.0mgPRN组BCVA改善优于康柏西普组(14.4 vs 4.2,p=0.039)。
关键数值与推荐
- 维持期2.0mgPRN组注射次数为2.8次(95%CI 1.8-3.7),少于康柏西普组的4.4次(95%CI 3.5-5.2)。
- 研究眼眼部不良事件发生率:1.0mgQ8组22.6%,1.0mgPRN组26.7%,2.0mgQ8组34.4%,2.0mgPRN组25.0%,康柏西普组32.3%。
- 研究眼眼部严重不良事件数:1.0mgQ8组1例,1.0mgPRN组0例,2.0mgQ8组1例,2.0mgPRN组2例,康柏西普组0例。
临床怎么用
- 作者推荐RC28-E 2.0mgPRN方案,因其在改善视力方面疗效优于康柏西普,尤其对血糖控制不佳患者,且维持期注射次数更少、安全性相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare different doses and dosing regimens of RC28-E, a novel bispecific antibody that simultaneously binds vascular endothelial growth factor-A (VEGF-A) and fibroblast growth factor-2 (FGF-2), with conbercept in patients with diabetic macular edema (DME). DESIGN: Prospective, randomised, active comparator-controlled, open-label, multicentre, phase 2 clinical trial.cente PARTICIPANTS: The trial enrolled patients aged 18 years or older with centre-involving DME, best-corrected visual acuity (BCVA) of 73 to 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and central subfield thickness (CST) of 300 µm or more. METHODS: Patients were assigned randomly to one of five treatment regimens: 1.0 mg RC28-E for three initial monthly doses and then every 8 weeks (1.0mgQ8); 1.0 mg RC28-E for five initial monthly doses and then on a pro re nata (PRN) basis (1.0mgPRN); 2.0 mg RC28-E for three initial monthly doses and then every 8 weeks (2.0mgQ8); 2.0 mg RC28-E for five initial monthly doses and then on a PRN basis (2.0mgPRN); or 0.5 mg conbercept for three initial monthly doses and then on a PRN basis. Assessments were made at baseline and every 4 weeks thereafter. MAIN OUTCOME MEASURES: The primary endpoint was the change in BCVA compared with baseline at 24 and 52 weeks. Secondary endpoints included the change in CST from baseline at 52 weeks; the proportion of patients who gained/lost ≥15 letters, ≥10 letters and >0 letter in BCVA; and the number of injections and safety outcomes. RESULTS: The trial enrolled 156 patients. Mean improvements in BCVA in the RC28-E groups at week 24 were 7.1, 11.0, 7.4 and 10.5 letters for 1.0mgQ8, 1.0mgPRN, 2.0mgQ8 and 2.0mgPRN regimens, respectively, versus 9.7 letters for the conbercept group (p=0.146). By week 52, the RC28-E groups exhibited respective mean BCVA enhancements of 5.5, 9.5, 9.2 and 9.7 letters, compared with 8.4 letters of the conbercept group (p=0.469). Mean reductions in CST in the RC28-E groups at week 52 were -163.2 µm, -136.9 µm, -142.5 µm and -153.6 µm, versus -160.7 µm for the conbercept group (p=0.948). The Per Protocol Set analysis indicated that at 24 weeks, the BCVA improvement in the 2.0mgPRN group was significantly greater than that in the conbercept group (14.0 vs 9.8, p=0.019). In patients with poor baseline glycaemic control (HbA1c ≥7.5%), the 2.0mgPRN group showed greater BCVA improvement than the conbercept group (14.4 vs 4.2, p=0.039) at week 52. During the maintenance phase, the 2.0mgPRN group had fewer injections (2.8, 95% CI 1.8 to 3.7) compared with the conbercept group (4.4, 95% CI 3.5 to 5.2). RC28-E was generally well tolerated. The incidence of ocular adverse events in study eyes was comparable between RC28-E groups (22.6% in 1.0mgQ8 group, 26.7% in 1.0mgPRN group, 34.4% in 2.0mgQ8 group, 25.0% in 2.0 mg PRN group) and conbercept group (32.3%). The number of ocular serious adverse events was 1 (1.0mgQ8), 0 (1.0mgPRN), 1 (2.0mgQ8), 2 (2.0mgPRN) and 0 (conbercept). CONCLUSIONS: Intravitreous RC28-E improved BCVA and CST in eyes with centre-involved DME. Compared with conbercept, the 2.0mgPRN regimen of RC28-E was recommended due to its superior efficacy in improving vision particularly for patients with poor glycaemic control, fewer treatment injections during the maintenance phase and comparable safety profile. TRIAL REGISTRATION NUMBER: NCT04782115.
引用
- Zhang W, Cheng S, Gu X, et al. Simultaneous inhibition of fibroblast growth factor-2 and vascular endothelial growth factor-a with RC28-E in diabetic macular edema: a phase 2 randomised trial. Br J Ophthalmol. 2025. PMID: 40122579. doi:10.1136/bjo-2024-326006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。